Adherence and patients’ experiences with the use of oral anticancer agents

References

• Timmers L, Beckeringh JJ, Herk-Sukel MPP, Boven E, Hugtenburg JG. Use and costs of oral anticancer agents in the Netherlands in the period 2000–2008. Pharmacoepidemiol Drug Saf 2012;21:1036–44.
   PubMed Web of Science ®Google Scholar
• Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. Answering patients’ needs: Oral alternatives to intravenous therapy. Oncologist 2001;6(Suppl 4):12–6.
   PubMed Web of Science ®Google Scholar
• Fallowfield L, Atkins L, Catt S, Cox A, Coxon C, Langridge C, et al. Patients’ preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer. Ann Oncol 2006;17: 205–10.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustova I, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: The X-ACT trial. Br J Cancer 2006;94:1122–9.
   PubMed Web of Science ®Google Scholar
• Benjamin L, Buthion V, Iskedjian M, Farah B, Rioufol C, Vidal-Trecan G. Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer. J Med Econ 2013; 16:96–107.
   PubMedGoogle Scholar
• Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009;59:56–66.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652–61.
   PubMed Web of Science ®Google Scholar
• Nilsson JLG, Andersson K, Bergkvist A, Bjorkman I, Brismar A, Moen J. Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients. Eur J Cancer Care (Engl) 2006;15:235–7.
   PubMed Web of Science ®Google Scholar
• Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. Br Med J 2006;333:15.
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon F, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381–8.
   PubMed Web of Science ®Google Scholar
• Mayer EL, Partridge AH, Harris LN, Gelman RS, Schumer ST, Burstein HJ, et al. Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat 2009;117:615–23.
   PubMed Web of Science ®Google Scholar
• Horne R, Hankins M, Jenkins R. The Satisfaction with Information about Medicines Scale (SIMS): A new measurement tool for audit and research. Qual Health Care 2001;10:135–40.
   PubMedGoogle Scholar
• Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality- of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76.
   PubMed Web of Science ®Google Scholar
• Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res 2006;60: 631–7.
   PubMed Web of Science ®Google Scholar
• Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1–24.
   Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–97.
   PubMed Web of Science ®Google Scholar
• Bhattacharya D, Easthall C, Willoughby KA, Small M, Watson S. Capecitabine non-adherence: Exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract 2012;18:333–42.
   PubMedGoogle Scholar
• Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, et al. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer 2011;19:1009–18.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: Adherence companion study 60104. J Clin Oncol 2010;28:2418–22.
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296–310.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010;26:2861–9.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: An observational patient-centered outcome study. Br J Cancer 2012;107:904–9.
   PubMed Web of Science ®Google Scholar
• DiMatteo MR. Social support and patient adherence to medical treatment: A meta-analysis. Health Psychol 2004; 23:207–18.
   PubMed Web of Science ®Google Scholar
• Cavalli-Bjorkman N, Glimelius B, Strang P. Equal cancer treatment regardless of education level and family support? A qualitative study of oncologists’ decision-making. Br Med J Open 2012;2.
   PubMed Web of Science ®Google Scholar
• Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47:555–67.
   PubMed Web of Science ®Google Scholar
• Baines T, Wittkowski A. A systematic review of the literature exploring illness perceptions in mental health utilising the self-regulation model. J Clin Psychol Med Settings 2012; 20:263–74.
   Web of Science ®Google Scholar